Cypherpunk Technologies reported a significant swing to profitability in the second quarter 2026, primarily driven by massive mark-to-market gains on its digital asset treasury as Zcash prices surged. While the company remains pre-revenue, its biotechnology subsidiary reached a critical regulatory milestone, securing FDA alignment for a registrational Phase 3 trial for its lead cancer candidate.
Key Highlights
- The company recorded a $46.0 million unrealized gain on its Zcash holdings as the asset's price rose from $243.35 to $400.09 during the quarter.
- Zcash treasury holdings increased to 323,394.38 units, representing approximately 1.92% of the total circulating supply of the Zcash network.
- Subsidiary Leap Therapeutics reached FDA alignment for a Phase 3 trial of sirexatamab in colorectal cancer and initiated a strategic process to potentially spin out or partner the program.